+91 9773134423[email protected]

Products Complies as per Regulatory requirements

PLGA is non-pharmacopeial Bioabsorbable polymer is widely

used for Drug delivery formulation as excipient in a

dosage forms.

Product List

CAS number:
26780-50-7
Systematic Name:

1, 4-Dioxane-2, 5-dione-1-DL-3, 6-dimethyl-1, 4-dioxane-2, 5-dione copolymer, Glycolide – lactide copolymer, Glycolide-DL-lactide copolymer, Glycolide-DL-lactide polymer, Lactide – glycolide copolymer, Lactomer, Poly(dl-lactide-co-glycolide), Poly(glycolide – lactide), Poly(glycolide-co-lactide), Polyglactin

Molecular Formula:

((C3H4O2)m x (C2H2O2)n

EPA Registry Name:

Polylactic acid-polyglycolic acid copolymer

Former CAS Number(s):

107760-14-5, 119652-89-0, 1255770-56-9, 130953-65-0, 31213-75-9, 339986-68-4

Substance Type:

Biodegradable Polymer, Excipient, Non-Active pharmaceutical ingredient, Nanoparticles, Nanomedicine, Bio-absorbable polymer.

Synonym:

PLGA, Poly(D,L-lactide-co-glycolide) ,Poly(DL-lactide-co-glycolide), PGLA .

Identification
Polymer
Ratio
End Group
Inherent Viscosity dl/g
Ask for Details
PLGA
50/50
COOH
0.15-0.25
DLG 50-3A
PLGA
50/50
COOH
0.25-0.40
🧾
DLG 50-5A
PLGA
50/50
COOH
0.40-0.55
🧾
DLG 50-6A
PLGA
50/50
COOH
0.55-0.65
🧾
DLG 50-8A
PLGA
50/50
COOH
0.55-0.65
🧾
DLG 50-2E
PLGA
50/50
ESTER
0.15-0.25
🧾
DLG 50-6E
PLGA
50/50
ESTER
0.55-0.65
🧾
DLG 50-7E
PLGA
50/50
ESTER
0.60-0.70
🧾
DLG 50-6P
PLGA-PEG
50/50
PEG
0.45-0.65
🧾
DLG 50-7P
PLGA-PEG
50/50
PEG
0.65-0.80
🧾
LG 50-7E
PLGA
50/50
ESTER
0.60-0.70
🧾
LG 50-2E
PLGA
50/50
ESTER
0.15-0.25
🧾
LG 50-7A
PLGA
50/50
COOH
0.60-0.70
🧾
LG 50-2A
PLGA
50/50
COOH
0.15-0.25
🧾
DLG 75-2A
PLGA
75/25
COOH
0.08-0.21
🧾
DLG 75-5A
PLGA
75/25
COOH
0.38-0.64
🧾
DLG 75-7A
PLGA
75/25
COOH
0.60-0.70
🧾
DLG 75-8A
PLGA
75/25
COOH
0.70-0.90
🧾
DLG 75-10A
PLGA
75/25
COOH
0.80-1.10
🧾
DLG 75-2E
PLGA
75/25
ESTER
0.15-0.30
🧾
DLG 75-4E
PLGA
75/25
ESTER
0.30-0.50
🧾
DLG 75-7E
PLGA
75/25
ESTER
0.66-0.80
🧾
DLG 75-9E
PLGA
75/25
ESTER
0.75-1.00
🧾
DLG 75-4A
PLGA
75/25
COOH
0.30-0.50
🧾
LG 75-2E
PLGA
75/25
ESTER
0.15-0.30
🧾
LG 75-9E
PLGA
75/25
ESTER
0.75-1.00
🧾
LG 75-2A
PLGA
75/25
COOH
0.15-0.30
🧾
LG 75-9A
PLGA
75/25
COOH
0.75-1.00
🧾
DLG 85-2A
PLGA
85/15
COOH
0.15-0.25
🧾
DLG 85-7A
PLGA
85/15
COOH
0.55-0.75
🧾
DLG 85-7E
PLGA
85/15
ESTER
0.55-0.75
🧾
DLG 85-12E
PLGA
85/15
ESTER
1.00-1.30
🧾
DLG 45-2A
PLGA
45/55
COOH
0.15-0.30
🧾
DLG 55-5A
PLGA
55/45
COOH
0.40-0.50
🧾
DLG 65-3A
PLGA
65/35
COOH
0.25-0.35
🧾
DLG 65-6A
PLGA
65/35
COOH
0.50-0.65
🧾
DLG 90-5A
PLGA
90/10
COOH
0.35-0.55
🧾
DLG 90-7A
PLGA
90/10
COOH
0.60-0.75
🧾
DLG 95-2A
PLGA
95/5
COOH
0.15-0.25
🧾
DLG 95-4A
PLGA
95/5
COOH
0.25-0.50
🧾
DLG 65-6E
PLGA
65/35
ESTER
0.50-0.65
🧾
DLL 10-15E
P(L/DL)LA
10/90
ESTER
1.30-1.70
🧾

 

The full name of PLA is Polylactic acid.

 

CAS Number: 26100-51-6

Other CAS Number: 33135-50-1

Systematic Name: Poly(2-hydroxy propionic acid)

Molecular Formula:((C3H4O2)m

EPA Registry Name: Polylactic acid

Substance Type: Biodegradable Polymer, Excipient, Non-Active pharmaceutical ingredient, Nanoparticles, Nanomedicine, Bio-absorbable polymer, Polymer for ACL Scrow.

Synonym: Polylactic acid, Poly(L-lactide), Poly(D,L-lactide) , Poly(D-lactide).

Acid Terminated


NHBP08 -DL 100-1A PDLLA 0/100 COOH 0.05-0.20 / 6-20
NHBP09 -DL 100-2A PDLLA 0/100 COOH 0.15-0.30 / 10-25
NHBP10 -DL 100-5A PDLLA 0/100 COOH 0.40-0.60 / 45-80
NHBP11 -DL 100-7A PDLLA 0/100 COOH 0.60-0.80 / 70-120

Ester Terminated

NHBP48 -DL 100-7E PDLLA 0/100 Ester 0.60-0.80 / 70-120
L-Lactide CAS 4511-42-6
D(+)-lactide – CAS 13076-17-0
DL-Lactide CAS 95-96-5
DL-Lactide CAS 95-96-5

Polyglycolic acid for sergical suture
PGA / Poly(2-hydroxyacetic acid) / 1.2 IV / Acid / 1Kg
End GroupEster - Ester Terminated, Acid - Acid Terminated, - Hydroxyl Terminated
*Not routinely stocked. Please call for a quote and availability.

*The price range for each 1gram of Polymer is $ 3.3 to 3.8 (USD)

Available variants​

01

Lactic acid isomers
L – Lactide
D – Lactide
DL – Lactide

02

Molecular Weight
10 kDa
to
120 kDa

03

End Group
Acid – Terminated
Ester – Terminated

04

Lactide & Glycolide (Compositions)
75:25 50:50
85:15 80:20
90:10 10:90

APPLICATION​

 

  • Poly(DL-lactide-co-glycolide) ester terminated; 50:50; IV 0.55-0.75 dL/g; Drug delivery (nanoparticles, in vitro, protein); particles were synthesized via a W/O/W emulsion technique; centrifugal fractioning used to control population distribution of particles.

  • Poly(DL-lactide-co-glycolide); MW 66 kDa; Drug delivery (nanoparticles, pDNA); Rat; prepared using a double emulsion solvent evaporation method; spinal cord injury; testing is done on the drug release, cytotoxicity, cellular uptake, and transfection.

  • Poly(DL-lactide-co-glycolide) acid terminated; 50:50; IV 0.15-0.25 dL/g; Drug delivery (nanoparticles, magnesium gluconate dihydrate); microspheres were fabricated by utilizing the double emulsion solvent evaporation technique with some modifications; “Cytotoxicity levels did not surpass the 15% cytotoxicity marker…which indicates sufficient biocompatibility”

  • Poly(DL-lactide-co-glycolide); 50:50; IV 0.76-0.94 dL/g; Drug delivery (nanoparticles, superoxide dismutase, catalase); rat (male Sprague-Dawley); double-emulsion solvent-evaporation method used for nanoparticle production; “delivery of Nano-CAT/SOD at the time of reperfusion effectively protects neuronal cells”

  • Poly(DL-lactide-co-glycolide); 50:50; IV 0.26–0.54 dL/g; Drug delivery (nanoparticles, paclitaxel, NIR dye SDB5700); mice (male, athymic, nude); Nanoparticles were prepared by a single oil-in-water emulsion solvent evaporation method.

  • Poly(DL-lactide-co-glycolide) acid-terminated; 50:50; IV 0.26-0.54 dL/g; Drug delivery (nanoparticles, ceftiofur); Rat (Sprague-Dawley); Nanoparticles were prepared by double-emulsion method; sustained release profile of drug for 20 days.

  • Poly(DL-lactide-co-glycolide); 50:50; IV 0.15-0.25 dL/g; Drug delivery (nanoparticles, oxcarbazepine); prepared at room temperature (22°C-23°C) by a modified solvent displacement method; particle size, size distribution, and zeta potential measurements (in vitro); drug release profile

  • Poly(DL-lactide-co-glycolide) ester terminated; 50:50; IV 0.67 dL/g; Drug delivery (nanoparticles, Nano sponge, a-toxin); mice; produced through nanoprecipitation in acetone.

  • Poly(DL-lactide-co-glycolide); 50:50; IV 0.55-0.75 dL/g; Drug delivery (nanoparticles, ovalbumin, Type 2 Herpes Simplex Virus glycoprotein D); C57BL/6 mice; Controlled delivery of stromal derived factor-1alpha from poly lactic-co-glycolic acid core-shell particles to recruit mesenchymal stem cells for cardiac regeneration.

  • Poly(DL-lactide-co-glycolide); 50:50; MW 31.3-57.6 kDa; Drug delivery (nanoparticles, stromal derived factor-1a); Coaxial electro spraying; sterilized using UV radiation.

  • Poly(L-lactide); MW 91-130 kDa; Drug delivery (nanoparticles, retinylamine); Mice (C57BL/6J); nanoparticles containing retinylamine were fabricated by a single emulsion technique; prevention of retinal degeneration.

  • Poly(DL-lactide-co-glycolide); 50:50; Drug delivery (nanoparticles, antigen); nanoparticles prepared using a double emulsion solvent evaporation method with modifications.

  • Poly(DL-lactide-co-glycolide) acid terminated; 50:50; IV 0.67 dL/g; Drug delivery (nanoparticles, docetaxel); rat (male, Sprague-Dawley); particles prepared in a nanoprecipitation process.

  • Poly(DL-lactide-co-glycolide); 50:50; Drug delivery (nanoparticles, bovine serum albumin); nanoparticles prepared by double emulsion solvent evaporation method with modifications.

  • Poly(DL-lactide-co-glycolide) ester terminated; 50:50; IV 0.55-0.75 dL/g; Drug delivery (nanoparticles, siRNA); nanoparticles were prepared using a modified water-in-oil-in-water double-emulsion solvent evaporation technique.

  • Poly(DL-lactide-co-glycolide) acid terminated; 50:50; IV 0.67 dL/g – MW 90 kDa; Drug delivery (nanoparticles, curcumin); formulated by solvent displacement method; IBR, cLABL peptides conjugated on the surface of PLGA nanoparticles using carbodiimide reaction; in vitro cytotoxicity testing